Kyverna Therapeutics (KYTX) Competitors

Kyverna Therapeutics logo
$4.70 -0.06 (-1.26%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$4.54 -0.16 (-3.38%)
As of 05:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KYTX vs. TYRA, OMER, VOR, SLN, and MLTX

Should you buy Kyverna Therapeutics stock or one of its competitors? Kyverna Therapeutics's main competitors and comparable companies include Tyra Biosciences (TYRA), Omeros (OMER), Vor Biopharma (VOR), Silence Therapeutics (SLN), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyverna Therapeutics compare to Tyra Biosciences?

Kyverna Therapeutics (NASDAQ:KYTX) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Kyverna Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 517.02%. Tyra Biosciences has a consensus target price of $47.40, indicating a potential upside of 142.21%. Given Kyverna Therapeutics' higher possible upside, research analysts plainly believe Kyverna Therapeutics is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

Kyverna Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Tyra Biosciences had 13 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 22 mentions for Tyra Biosciences and 9 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat Tyra Biosciences' score of -0.20 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Tyra Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A

Tyra Biosciences' return on equity of -40.12% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -86.87% -65.74%
Tyra Biosciences N/A -40.12%-37.62%

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Tyra Biosciences beats Kyverna Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Omeros?

Kyverna Therapeutics (NASDAQ:KYTX) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Omeros had 14 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 23 mentions for Omeros and 9 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat Omeros' score of 0.34 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Omeros
1 Very Positive mention(s)
5 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Neutral

Kyverna Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Omeros has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market.

Kyverna Therapeutics' return on equity of -86.87% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -86.87% -65.74%
Omeros N/A -261.02%68.52%

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A
OmerosN/AN/A-$3.35M$1.2810.88

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics presently has a consensus target price of $29.00, suggesting a potential upside of 517.02%. Omeros has a consensus target price of $30.33, suggesting a potential upside of 117.91%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Omeros.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Kyverna Therapeutics beats Omeros on 7 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Vor Biopharma?

Kyverna Therapeutics (NASDAQ:KYTX) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A
Vor BiopharmaN/AN/AN/AN/AN/A

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics currently has a consensus price target of $29.00, suggesting a potential upside of 517.02%. Vor Biopharma has a consensus price target of $38.29, suggesting a potential upside of 110.59%. Given Kyverna Therapeutics' higher probable upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Vor Biopharma
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Kyverna Therapeutics and 4 mentions for Vor Biopharma. Kyverna Therapeutics' average media sentiment score of 0.52 beat Vor Biopharma's score of 0.48 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vor Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vor Biopharma's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -86.87% -65.74%
Vor Biopharma N/A N/A N/A

Kyverna Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market.

Summary

Kyverna Therapeutics and Vor Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Silence Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$560K2,197.45-$88.61M-$1.07N/A
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A

Silence Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 21.21%. Kyverna Therapeutics has a consensus price target of $29.00, indicating a potential upside of 517.02%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 9 mentions for Kyverna Therapeutics and 5 mentions for Silence Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat Silence Therapeutics' score of 0.05 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Silence Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Kyverna Therapeutics' return on equity of -86.87% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence Therapeutics-8,943.86% -102.72% -43.70%
Kyverna Therapeutics N/A -86.87%-65.74%

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Kyverna Therapeutics beats Silence Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.67N/A
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A

MoonLake Immunotherapeutics currently has a consensus target price of $31.33, suggesting a potential upside of 178.52%. Kyverna Therapeutics has a consensus target price of $29.00, suggesting a potential upside of 517.02%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.60
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 13 mentions for MoonLake Immunotherapeutics and 9 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat MoonLake Immunotherapeutics' score of -0.09 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics' return on equity of -79.95% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -79.95% -56.40%
Kyverna Therapeutics N/A -86.87%-65.74%

MoonLake Immunotherapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

Summary

Kyverna Therapeutics beats MoonLake Immunotherapeutics on 8 of the 13 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KYTX vs. The Competition

MetricKyverna TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$300.94M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / SalesN/A15.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book2.234.184.463.72
Net Income-$161.31M-$24.15M$3.52B$393.10M
7 Day Performance-8.20%-7.78%-5.92%-5.76%
1 Month Performance-17.11%-5.96%-4.58%-7.14%
1 Year Performance-39.97%-8.08%-1.93%-7.46%

Kyverna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KYTX
Kyverna Therapeutics
2.133 of 5 stars
$4.70
-1.3%
$29.00
+517.0%
-34.4%$300.94MN/AN/A149
TYRA
Tyra Biosciences
2.4403 of 5 stars
$21.00
-5.8%
$47.20
+124.8%
+23.1%$1.25BN/AN/A87
OMER
Omeros
3.1615 of 5 stars
$17.30
-1.4%
$30.33
+75.3%
+53.3%$1.25BN/A13.52175
VOR
Vor Biopharma
2.1669 of 5 stars
$19.56
-2.1%
$38.29
+95.7%
+81.4%$1.20BN/AN/A76
SLN
Silence Therapeutics
2.9869 of 5 stars
$19.79
+0.2%
$24.00
+21.3%
+195.5%$1.19B$560KN/A88

Related Companies and Tools


This page (NASDAQ:KYTX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners